Takeda Pharmaceutical (OTCPK:TKPHF) gets a positive CHMP opinion
recommending approval of the subcutaneous form of vedolizumab biologic
for maintenance therapy in adults with moderately to severely active
ulcerative colitis or Crohn’s disease.
The opinion of the Committee for Medicinal
Products for Human Use of the European Medicines Agency will now be
reviewed by the European Commission.
If approved, vedolizumab will become the only
maintenance therapy for UC or CD with both intravenous and subcutaneous
formulations across the European Union.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.